Intravenous cell therapy for acute renal failure with serum amyloid a protein-reprogrammed cells

Katherine J. Kelly, Barbara Kluve-Beckerman, Jizhong Zhang, Jesus H. Dominguez

Research output: Contribution to journalArticle

14 Scopus citations


Serum amyloid A protein (SAA), a prominent component of the acute-phase response, is strongly expressed in developing and repairing kidneys and promotes tubulogenesis. Accordingly, we reprogrammed relatively undifferentiated NRK52E cells with the mouse SAA1.1 gene and transplanted SAA-positive and -negative cells into rats with acute renal failure. We found that SAA-positive cells accelerated renal recovery in three models of acute renal failure: gentamicin nephrotoxicity, cisplatin-mediated renal injury, and ischemia-reperfusion renal injury. The dramatic improvement of renal failure was demonstrable within 2 days, consistent with an early paracrine effect. However, abundant donor cells were also found integrated in the healing tubular architecture after 7 days. We conclude that infusions of SAA-positive cells promote renal recovery after acute renal failure and offer a potentially powerful and novel therapy of renal failure.

Original languageEnglish (US)
Pages (from-to)F453-F464
JournalAmerican Journal of Physiology - Renal Physiology
Issue number2
StatePublished - Aug 1 2010


  • Acute-phase response
  • Tubulogenesis

ASJC Scopus subject areas

  • Physiology
  • Urology

Fingerprint Dive into the research topics of 'Intravenous cell therapy for acute renal failure with serum amyloid a protein-reprogrammed cells'. Together they form a unique fingerprint.

  • Cite this